ArticleJournal of periodontology2026
Roles of CCL2 in peri-implantitis and its potential as a treatment target: An animal study.
Article in Journal of periodontology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundCC-chemokine ligand 2 (CCL2) plays pivotal roles in many osteoimmune disorders, while its role in peri-implantitis is unknown. The main research question aimed to address in this study is investigating the specific roles of CCL2 in peri-implantitis and assessing the preventive and therapeutic effects of bindarit on experimental peri-implantitis.
methodsFirstly, the expression profile of CC-chemokine receptor 2 ligands in human peri-implantitis was ascertained by processing and analyzing datasets from the Gene Expression Omnibus database. Then the experimental peri-implantitis model was established in mice by suture ligation, and the soft tissue inflammation and hard tissue resorption were compared in CCL2 knockout (Ccl2
resultsCCL2 demonstrated a significant predominant expression among the ligands of CC-chemokine receptor 2 in human peri-implantitis. CCL2 was significantly upregulated in the ligature-induced peri-implantitis model (p = 0.0007), and CCL2 deficiency resulted in significantly decreased monocytes/macrophages infiltration in peri-implant tissue (CD45
conclusionsThe findings of this study suggest that CCL2 may serve as a potential target for peri-implantitis treatment by mediating peri-implant host immune response to modulate local inflammation and bone resorption, offering a new direction for the development of immunotherapeutic drugs for this condition. PLAIN LANGUAGE SUMMARY: Peri-implantitis, an inflammatory condition that impacts the longevity of dental implants, poses considerable challenges due to the limited effectiveness of current treatment methods. This study aimed to understand the role of CC-chemokine ligand 2 (CCL2) in this condition. In our study, CCL2 was discovered to be the primary ligand of CC-chemokine receptor 2 in peri-implantitis. Lab tests using a mouse model revealed that in the absence of CCL2, inflammation and bone loss were reduced. Furthermore, this study confirmed the effect of a drug called bindarit, which inhibits CCL2, in treating experimental peri-implantitis. Investigating the specific roles of CCL2 and assessing the potential benefits of bindarit in managing peri-implantitis provide a scientific foundation for exploring new treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.